Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1 Academic Article uri icon

Overview

MeSH Major

  • Anilides
  • Prostatic Neoplasms, Castration-Resistant
  • Pyridines

abstract

  • Cabozantinib did not significantly improve OS compared with prednisone in heavily treated patients with mCRPC and progressive disease after docetaxel and abiraterone and/or enzalutamide. Cabozantinib had some activity in improving BSR, rPFS, SSEs, CTC conversions, and bone biomarkers but not PSA outcomes.

publication date

  • September 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.65.5597

PubMed ID

  • 27400947

Additional Document Info

start page

  • 3005

end page

  • 13

volume

  • 34

number

  • 25